FOLEY & LARDNER LLP

FOLEY & LARDNER LLP
ATTORNEYS AT LAW
WASHINGTON HARBOUR
3000 K STREET, N.W., SUITE 600
WASHINGTON, D.C. 20007-5143
202.672.5300 TEL
202.672.5399 FAX
www.foley.com
WRITER'S DIRECT LINE
202.672.5430
drosen@foley.com EMAIL

September 26, 2019

VIA ELECTRONIC SUBMISSION

Division of Dockets Management
Food and Drug Administration
Department of Health and Human Services
5630 Fishers Lane, Room 1061
Rockville, MD 20852

CITIZEN PETITION

The undersigned submits this Citizen Petition pursuant to Section 505(j) of the Federal Food, Drug and Cosmetic Act and in accordance with 21 CFR § 10.25(a) and 10.30, to request the Commissioner of Food and Drug Administration to designate a suitable additional Reference Standard ("RS") for purposes of submitting an abbreviated new drug application ("ANDA") for Oxybutynin Chloride Extended Release Tablets 5 mg, 10 mg and 15 mg.

I. Action Requested

This Petitioner respectfully requests that the Commissioner designate an additional RS status for Oxybutynin Chloride Extended Release Tablets 15 mg, specifically the ANDA held by Accord Healthcare Inc. (ANDA No. 207138)

II. Statement of Grounds

Please note that the FDA's Orange Book identifies RLD NDA #020897- DITROPAN XL (Oxybutynin Chloride) Extended Release Tablets 15 mg as discontinued.

As such, quantities of the RS Product are required in order to conduct studies (In-Vivo Studies as per BE recommendation) to establish bioequivalence with the RS in absence of RLD which is discontinued. The present RS for Oxybutynin Chloride Extended Release Tablets 15 mg is held by Mylan Pharmaceuticals Inc. (ANDA No. 076644).

Despite diligent efforts to obtain sufficient quantities of the present RS for the Product, samples are not available in the market to conduct required studies.

Please note Oxybutynin Chloride Extended Release Tablets 15 mg manufactured by Accord Healthcare Inc., (ANDA No. 207138) are available in market.

The sale of reference standard strength 15 mg manufactured by Accord Healthcare Inc. is highest across different application holders as per IMS health database as on Aug 2019.

Per the Agency's published Draft Guidance for Industry, Referencing Approved Drug Products in ANDA Submissions (Jan. 2017), "If there is a reference standard in the 'Active Section' of the Orange Book for a drug product the applicant intends to duplicate but there are limited or no quantities in distribution, or a potential ANDA applicant believes a reference standard other than the one selected by FDA is appropriate, then the potential applicant may submit a citizen petition under 21 CFR 10.25(a) and 10.30 to request that FDA select that different listed drug also as a reference standard."

Conclusion

For the above stated reasons, this Citizen Petition should be granted.

III. Environmental Impact

The Petitioner believes that this petition does not require an environmental impact analysis report under 21 C.F.R. § 25.1(g).

IV. Economic Impact

An economic impact report is required only when requested by the Administration and such report has not been requested under 21 C.F.R. § 10.30(b).

V. Certification

The Petitioner certifies that, to the best of its knowledge and belief, this Petition includes all of the information and views on which the Petition relies and that it includes representative data and information known to the Petitioner, which are unfavorable to the Petitioner.

Respectfully submitted,

David L. Rosen, BS Pharm., JD
Foley & Lardner LLP